Zobrazeno 1 - 10
of 167
pro vyhledávání: '"Denise M. Wolf"'
Autor:
Silver Alkhafaji, Denise M. Wolf, Mark Jesus M. Magbanua, Laura J. van ‘t Veer, John W. Park, Laura Esserman, Rita A. Mukhtar
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract This is a secondary data analysis of the TIPPING study, which included 1,121 patients with stage I-III breast cancer who had enumeration of CTCs (by either CellSearch or immunomagnetic enrichment and flow cytometry [IE/FC]) and disseminated
Externí odkaz:
https://doaj.org/article/6aee9c4d7c8f47af9df92861a7cd3949
Autor:
Tessa G. Steenbruggen, Denise M. Wolf, Michael J. Campbell, Joyce Sanders, Sten Cornelissen, Bram Thijssen, Roberto A. Salgado, Christina Yau, Nick O-Grady, Amrita Basu, Rajith Bhaskaran, Lorenza Mittempergher, Gillian L. Hirst, Jean-Philippe Coppe, Marleen Kok, Gabe S. Sonke, Laura J. van ‘t Veer, Hugo M. Horlings
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-19 (2023)
Abstract Background Despite major improvements in treatment of HER2-positive metastatic breast cancer (MBC), only few patients achieve complete remission and remain progression free for a prolonged time. The tumor immune microenvironment plays an imp
Externí odkaz:
https://doaj.org/article/cd4ee360474c49639be138517e337159
Autor:
Yiwey Shieh, Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart, Scott Huntsman, Donglei Hu, Jovia L. Nierenberg, Pooja Middha, Rachel S. Heise, Yushu Shi, Linda Kachuri, Qianqian Zhu, Song Yao, Christine B. Ambrosone, Marilyn L. Kwan, Bette J. Caan, John S. Witte, Lawrence H. Kushi, Laura van ‘T Veer, Laura J. Esserman, Elad Ziv
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling.
Externí odkaz:
https://doaj.org/article/138d8faa316e4fb8af5632688f767d95
Autor:
Katharine Yu, Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay, James E. Korkola, Gillian L. Hirst, Smita Asare, Angela DeMichele, Nola Hylton, Douglas Yee, Laura Esserman, Laura van ‘t Veer, Marina Sirota
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionDrug resistance is a major obstacle in cancer treatment and can involve a variety of different factors. Identifying effective therapies for drug resistant tumors is integral for improving patient outcomes.MethodsIn this study, we applied
Externí odkaz:
https://doaj.org/article/c9d670c177794b0ba2003ce13caa9f43
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Rosalyn W. Sayaman, Mohamad Saad, Carolina Heimann, Donglei Hu, Khalid Kunji, Jessica Roelands, Denise M. Wolf, Scott Huntsman, Michele Ceccarelli, Vésteinn Thorsson, Elad Ziv, Davide Bedognetti
Publikováno v:
STAR Protocols, Vol 3, Iss 4, Pp 101809- (2022)
Summary: Germline genetic variants modulate human immune response. We present analytical pipelines for assessing the contribution of hosts’ genetic background to the immune landscape of solid tumors using harmonized data from more than 9,000 patien
Externí odkaz:
https://doaj.org/article/0ca429312e1c4a1f8fe9a9562396dc10
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Information regarding response to past treatments may provide clues concerning the classes of drugs most or least likely to work for a particular metastatic or neoadjuvant early stage breast cancer patient. However, currently ther
Externí odkaz:
https://doaj.org/article/faeb29cb14ea49379fa6e3a5193643a6
Autor:
Mark Jesus M. Magbanua, Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart, David C. Newitt, Jessica Gibbs, Amy L. Delson, Ekaterina Kalashnikova, Alexey Aleshin, Bernhard Zimmermann, A. Jo Chien, Debu Tripathy, Laura Esserman, Nola Hylton, Laura van ‘t Veer
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract We investigated whether serial measurements of circulating tumor DNA (ctDNA) and functional tumor volume (FTV) by magnetic resonance imaging (MRI) can be combined to improve prediction of pathologic complete response (pCR) and estimation of
Externí odkaz:
https://doaj.org/article/fc14e93945954cfb88f54bbbdcc007fe
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
Autor:
Imke H. Bartelink, Brendan Prideaux, Gregor Krings, Lisa Wilmes, Pei Rong Evelyn Lee, Pan Bo, Byron Hann, Jean-Philippe Coppé, Diane Heditsian, Lamorna Swigart-Brown, Ella F. Jones, Sergey Magnitsky, Ron J Keizer, Niels de Vries, Hilde Rosing, Nela Pawlowska, Scott Thomas, Mallika Dhawan, Rahul Aggarwal, Pamela N. Munster, Laura J. Esserman, Weiming Ruan, Alan H. B. Wu, Douglas Yee, Véronique Dartois, Radojka M. Savic, Denise M. Wolf, Laura van ’t Veer
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-17 (2017)
Abstract Background Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some
Externí odkaz:
https://doaj.org/article/36493b79564d44c2b1b8ca3d6cd7f195